CG Oncology, Inc. is an American biotechnology company focused on the development of immunotherapeutic drugs for the treatment of cancer. The company specializes in developing therapies that activate the patient's immune system to target and destroy tumor cells. Its leading product is CUE-101, an immunotherapy aimed at treating head and neck cancer. CG Oncology leverages advanced technologies in immunology and oncology to develop innovative treatment approaches for cancer patients who lack sufficient therapeutic options. The company is in clinical development stages, and its common stock is publicly traded on the stock exchange.